Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
CARotid Plaque Stabilization and Regression with Evolocumab (CARUSO)
2020-005663-31Phase 4Active
- Sponsor
- Azienda Ospedaliera Ordine Mauriziano di Torino
- Start
- Jun 2021
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 4, randomised trial of evolocumab in Carotid artery disease (CAD), atherosclerotic disease and carotid atheroma (CAS) (2 arms), sponsored by Azienda Ospedaliera Ordine Mauriziano di Torino. Primary endpoints: Morphological stabilization of carotid plaque at 6 months and Morphological regression of carotid plaque at 12 months. Started Jun 2021; status: active.
02
Drugs
evolocumab
03
Conditions
Carotid artery disease (CAD)atherosclerotic diseasecarotid atheroma (CAS)
Beyond the preview
Go deeper on 2020-005663-31.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2020-005663-31.